137 related articles for article (PubMed ID: 36680333)
21. Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met.
Chen JJ; Sun X; Mao QQ; Jiang XY; Zhao XG; Xu WJ; Zhong L
Kaohsiung J Med Sci; 2020 Mar; 36(3):196-205. PubMed ID: 31749294
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients.
Lu T; Li C; Xiang C; Gong Y; Peng W; Chen C
Biomed Res Int; 2022; 2022():7823191. PubMed ID: 35313629
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
24. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
26. Elevated CDK5R1 predicts worse prognosis in hepatocellular carcinoma based on TCGA data.
Zeng Z; Cao Z; Zhang E; Huang H; Tang Y
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33346796
[TBL] [Abstract][Full Text] [Related]
27. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis.
Wang Y; He D; Yang L; Wen B; Dai J; Zhang Q; Kang J; He W; Ding Q; He D
Biochem Biophys Res Commun; 2015 Jul; 463(3):458-65. PubMed ID: 26043685
[TBL] [Abstract][Full Text] [Related]
28. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.
Wei ZL; Zhou X; Lan CL; Huang HS; Liao XW; Mo ST; Wei YG; Peng T
BMC Gastroenterol; 2022 Feb; 22(1):77. PubMed ID: 35193513
[TBL] [Abstract][Full Text] [Related]
30. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
[TBL] [Abstract][Full Text] [Related]
31. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma.
Zeng Z; Jiang X; Pan Z; Zhou R; Lin Z; Tang Y; Cui Y; Zhang E; Cao Z
Aging (Albany NY); 2021 Oct; 13(19):22802-22829. PubMed ID: 34607313
[TBL] [Abstract][Full Text] [Related]
32. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma.
Zhu S; Huang X; Zhang K; Tan W; Lin Z; He Q; Chen Y; Shang C
Cancer Med; 2019 Dec; 8(18):7679-7692. PubMed ID: 31674731
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of real hub genes in hepatocellular carcinoma based on weighted gene co-expression network analysis.
Qiao Y; Yuan F; Wang X; Hu J; Mao Y; Zhao Z
Cancer Biomark; 2022; 35(2):227-243. PubMed ID: 36120772
[TBL] [Abstract][Full Text] [Related]
34. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.
Xiong C; Wang Z; Wang G; Zhang C; Jin S; Jiang G; Bai D
Invest New Drugs; 2021 Oct; 39(5):1439-1453. PubMed ID: 33942202
[TBL] [Abstract][Full Text] [Related]
35. Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells.
Qiu S; Zhong C; Zhao B; Li G; Wang J; Jehan S; Li J; Zhao X; Li D; Sui G
Biochim Biophys Acta Gen Subj; 2021 Jul; 1865(7):129911. PubMed ID: 33862123
[TBL] [Abstract][Full Text] [Related]
36. Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma.
Mo M; Ma X; Luo Y; Tan C; Liu B; Tang P; Liao Q; Liu S; Yu H; Huang D; Zeng X; Qiu X
BMC Cancer; 2022 Oct; 22(1):1098. PubMed ID: 36289466
[TBL] [Abstract][Full Text] [Related]
37. Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma.
Tsai HW; Ho CL; Cheng SW; Lin YJ; Chen CC; Cheng PN; Yen CJ; Chang TT; Chiang PM; Chan SH; Ho CH; Chen SH; Wang YW; Chow NH; Lin JC
World J Gastroenterol; 2018 Mar; 24(10):1152-1166. PubMed ID: 29563759
[TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA RUSC1-AS-N indicates poor prognosis and increases cell viability in hepatocellular carcinoma.
Tang R; Wu JC; Zheng LM; Li ZR; Zhou KL; Zhang ZS; Xu DF; Chen C
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):388-396. PubMed ID: 29424895
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Novel Circadian Rhythm-Related Signature to Predict the Prognosis of the Patients with Hepatocellular Carcinoma.
Wu Y; Shen C; Wang X; Zhao W; Li Y; He X; Chen Y; Liu J; Wu X; Shen A
Biomed Res Int; 2022; 2022():4263261. PubMed ID: 35993051
[TBL] [Abstract][Full Text] [Related]
40. Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways.
Jiao Y; Li Y; Ji B; Cai H; Liu Y
J Gastrointestin Liver Dis; 2019 Dec; 28(4):439-447. PubMed ID: 31826070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
